Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. It is developing cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, natural killer cell therapy technology. The company is also developing a multi-antigen CAR T technology licensed from the University of Pittsburgh, and the GEAR cell therapy and companion diagnostic platforms, which are developing with VyGen-Bio and medical researchers at the Karolinska Institute. Its Product Pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania. more
Time Frame | COEP | Sector | S&P500 |
---|---|---|---|
1-Week Return | 22.07% | 0.31% | -1.26% |
1-Month Return | 115.71% | 0.6% | -4.16% |
3-Month Return | 101.96% | -9.44% | -0.46% |
6-Month Return | 37.33% | -5.15% | 3.58% |
1-Year Return | -29.09% | 0.33% | 22.47% |
3-Year Return | -95.88% | 4.53% | 25.13% |
5-Year Return | -95.84% | 35.98% | 77.7% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 30.76K | 75.00K | - | - | - | [{"date":"2020-12-31","value":41.01,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
Cost of Revenue | 964.22K | 447.41K | 1.00M | 1.00M | 1.00M | [{"date":"2020-12-31","value":96.29,"profit":true},{"date":"2021-12-31","value":44.68,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":99.99,"profit":true}] |
Gross Profit | (933.46K) | (372.41K) | (1.00M) | (1.00M) | (1.00M) | [{"date":"2020-12-31","value":-93345600,"profit":false},{"date":"2021-12-31","value":-37241300,"profit":false},{"date":"2022-12-31","value":-100138400,"profit":false},{"date":"2023-12-31","value":-100138400,"profit":false},{"date":"2024-12-31","value":-100123600,"profit":false}] |
Gross Margin | (3034.54%) | (496.55%) | (Infinity%) | (Infinity%) | - | [{"date":"2020-12-31","value":-3034.54,"profit":false},{"date":"2021-12-31","value":-496.55,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
Operating Expenses | 5.78M | 14.12M | 34.20M | 34.20M | 20.49M | [{"date":"2020-12-31","value":16.9,"profit":true},{"date":"2021-12-31","value":41.29,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":59.92,"profit":true}] |
Operating Income | (6.86M) | (14.05M) | (34.20M) | (34.20M) | (21.49M) | [{"date":"2020-12-31","value":-686140300,"profit":false},{"date":"2021-12-31","value":-1404593200,"profit":false},{"date":"2022-12-31","value":-3419596400,"profit":false},{"date":"2023-12-31","value":-3419596400,"profit":false},{"date":"2024-12-31","value":-2149112500,"profit":false}] |
Total Non-Operating Income/Expense | (2.44M) | 409.52K | (3.60M) | (3.51M) | - | [{"date":"2020-12-31","value":-596.57,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-878.27,"profit":false},{"date":"2023-12-31","value":-858.19,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
Pre-Tax Income | (9.16M) | (13.45M) | (37.57M) | (37.57M) | (21.27M) | [{"date":"2020-12-31","value":-915628600,"profit":false},{"date":"2021-12-31","value":-1344928000,"profit":false},{"date":"2022-12-31","value":-3757421700,"profit":false},{"date":"2023-12-31","value":-3757421700,"profit":false},{"date":"2024-12-31","value":-2126653700,"profit":false}] |
Income Taxes | (2.15M) | 972.92K | 3.39M | 3.39M | - | [{"date":"2020-12-31","value":-63.26,"profit":false},{"date":"2021-12-31","value":28.67,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
Income After Taxes | (7.01M) | (14.42M) | (40.97M) | (40.97M) | - | [{"date":"2020-12-31","value":-700959500,"profit":false},{"date":"2021-12-31","value":-1442219900,"profit":false},{"date":"2022-12-31","value":-4096775900,"profit":false},{"date":"2023-12-31","value":-4096775900,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (9.16M) | (13.45M) | (37.57M) | (20.19M) | - | [{"date":"2020-12-31","value":-915628600,"profit":false},{"date":"2021-12-31","value":-1344928000,"profit":false},{"date":"2022-12-31","value":-3757421700,"profit":false},{"date":"2023-12-31","value":-2018516000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
Net Income | (7.01M) | (14.42M) | (40.97M) | (40.97M) | (21.27M) | [{"date":"2020-12-31","value":-700959500,"profit":false},{"date":"2021-12-31","value":-1442219900,"profit":false},{"date":"2022-12-31","value":-4096775900,"profit":false},{"date":"2023-12-31","value":-4096775900,"profit":false},{"date":"2024-12-31","value":-2126653700,"profit":false}] |
EPS (Diluted) | (0.44) | (0.41) | (3.41) | (0.87) | - | [{"date":"2020-12-31","value":-43.81,"profit":false},{"date":"2021-12-31","value":-41,"profit":false},{"date":"2022-12-31","value":-340.96,"profit":false},{"date":"2023-12-31","value":-87.27,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
COEP | |
---|---|
Cash Ratio | 0.33 |
Current Ratio | 0.40 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
COEP | |
---|---|
ROA (LTM) | -187.35% |
ROE (LTM) | -1481.29% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
COEP | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.44 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.54 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
COEP | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 45.68 |
P/B | 3.51 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Coeptis Therapeutics Inc (COEP) share price today is $8.24
Yes, Indians can buy shares of Coeptis Therapeutics Inc (COEP) on Vested. To buy Coeptis Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in COEP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Coeptis Therapeutics Inc (COEP) via the Vested app. You can start investing in Coeptis Therapeutics Inc (COEP) with a minimum investment of $1.
You can invest in shares of Coeptis Therapeutics Inc (COEP) via Vested in three simple steps:
The 52-week high price of Coeptis Therapeutics Inc (COEP) is $13.58. The 52-week low price of Coeptis Therapeutics Inc (COEP) is $2.31.
The price-to-earnings (P/E) ratio of Coeptis Therapeutics Inc (COEP) is
The price-to-book (P/B) ratio of Coeptis Therapeutics Inc (COEP) is 3.51
The dividend yield of Coeptis Therapeutics Inc (COEP) is 0.00%
The market capitalization of Coeptis Therapeutics Inc (COEP) is $16.94M
The stock symbol (or ticker) of Coeptis Therapeutics Inc is COEP